Immunoengineering with biomaterials for enhanced cancer immunotherapy
- 14 January 2018
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 10 (4) , e1506
Abstract
Cancer immunotherapy has recently shown dramatic clinical success inducing durable response in patients of a wide variety of malignancies. Further improvement of the clinical outcome with immune related cancer treatment requests more exquisite manipulation of a patient's immune system with increased immunity against diseases while mitigating the toxicities. To meet this challenge, biomaterials applied to immunoengineering are being developed to achieve tissue‐ and/or cell‐specific immunomodulation and thus could potentially enhance both the efficacy and safety of current cancer immunotherapies. Here, we review the recent advancement in the field of immunoengineering using biomaterials and their applications in promoting different modalities of cancer immunotherapies, with focus on cell‐, antibody‐, immunomodulator‐, and gene‐based immune related treatments and their combinations with conventional therapies. Challenges and opportunities are discussed in applying biomaterials engineering strategies in the development of future cancer immunotherapies.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Implantable Materials and Surgical Technologies > Nanomaterials and ImplantsKeywords
Funding Information
- Novartis Foundation (17A058)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (315230_173243)
This publication has 175 references indexed in Scilit:
- Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticlesBiomaterials, 2012
- Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapyNature Materials, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Interleukin-15 biology and its therapeutic implications in cancerTrends in Pharmacological Sciences, 2012
- Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapyBiomaterials, 2011
- Membrane Anchored Immunostimulatory Oligonucleotides for In Vivo Cell Modification and Localized ImmunotherapyAngewandte Chemie International Edition, 2011
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumorsCancer Biology & Therapy, 2010
- Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer ImmunotherapyJournal of the American Chemical Society, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligandProceedings of the National Academy of Sciences, 2007